Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 4
1971 6
1972 6
1973 7
1974 5
1975 10
1976 7
1977 9
1978 8
1979 5
1980 8
1981 4
1982 4
1983 10
1984 10
1985 14
1986 22
1987 25
1988 17
1989 22
1990 21
1991 20
1992 12
1993 24
1994 19
1995 18
1996 15
1997 16
1998 12
1999 22
2000 17
2001 16
2002 16
2003 14
2004 14
2005 17
2006 11
2007 20
2008 19
2009 10
2010 19
2011 12
2012 12
2013 13
2014 14
2015 10
2016 12
2017 15
2018 15
2019 16
2020 22
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

679 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic Vaccines for HPV-Associated Malignancies.
Smalley Rumfield C, Roller N, Pellom ST, Schlom J, Jochems C. Smalley Rumfield C, et al. Among authors: schlom j. Immunotargets Ther. 2020 Oct 7;9:167-200. doi: 10.2147/ITT.S273327. eCollection 2020. Immunotargets Ther. 2020. PMID: 33117742 Free PMC article. Review.
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT. Sun L, et al. Among authors: schlom j. JCI Insight. 2019 Apr 4;4(7):e126853. doi: 10.1172/jci.insight.126853. eCollection 2019 Apr 4. JCI Insight. 2019. PMID: 30944253 Free PMC article.
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL. Strauss J, et al. Among authors: schlom j. Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3. Clin Cancer Res. 2018. PMID: 29298798 Free PMC article. Clinical Trial.
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, Zebala JA, Clavijo PE, Allen C. Greene S, et al. Among authors: schlom j. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. doi: 10.1158/1078-0432.CCR-19-2625. Epub 2019 Dec 17. Clin Cancer Res. 2020. PMID: 31848188 Free PMC article.
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Karzai F, et al. Among authors: schlom j. J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2. J Immunother Cancer. 2018. PMID: 30514390 Free PMC article.
679 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page